SG
CELG

Swarthmore Group’s Celgene Corp CELG Stock Holding History

Swarthmore Group’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,675
Closed -$244K – 64
2017
Q3 		$244K Buy
+1,675
New +$228K 0.06% 53
2017
Q2 		– Sell
-5,000
Closed -$622K – 48
2017
Q1 		$622K Hold
5,000
– – 0.1% 38
2016
Q4 		$579K Buy
+5,000
New +$557K 0.09% 38

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Swarthmore Group's CELG Position: Q4 2017 in Review

Swarthmore Group sold out of Celgene Corp (CELG) in Q4 2017, closing a stake of 1,675 shares — an estimated $244K sold.

Swarthmore Group first reported a position in CELG in Q4 2016 and held it in 3 quarters. The position peaked at $622K in Q1 2017. 1,470 funds tracked by Wall St. Rank hold CELG as of Q4 2017.

  • Swarthmore Group reported no remaining Celgene Corp position as of Q4 2017 after selling out during the quarter.
  • Swarthmore Group sold 1,675 Celgene Corp shares in Q4 2017, an estimated $244K.
  • Swarthmore Group first reported a position in Celgene Corp in Q4 2016 and held it in 3 quarters.
  • Swarthmore Group's Celgene Corp position peaked at $622K in Q1 2017.
  • 1,470 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2017.

Based on Swarthmore Group's 13F filing for Q4 2017, filed 18 Jan 2018.